A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Completed · Phase 1/Phase 2
Conditions studied: Non-Hodgkin's Lymphoma, Hodgkin's Disease
In brief
This study was an early-phase trial arranged into two phases. The Phase I portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Phase II was intended to assess the activity, safety and tolerability of SB-743921 in patients with Indolent and Aggressive Non-Hodgkin's Lymphomas exclusively. The Phase II portion of the study was not initiated.
Key facts
- Study ID
- NCT00343564
- Run by
- Cytokinetics
- People needed
- 68
- Starts
- 2006-04-01
- Expected to finish
- 2010-07-01
- Last updated by the study team
- 2020-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Cornell University Medical Center — New York, New York, United States
- Memorial Sloan-Kettering Caner Center — New York, New York, United States
- Herbert Irving Comprehensive Cancer Center — New York, New York, United States
- University of North Carolina — Chapel Hill, North Carolina, United States
- Sarah Cannon Cancer Research Institute — Nashville, Tennessee, United States
- Russian Medical Academy of Postgraduate Education — Moscow, Russia
- St. Petersburg State PAVLOV Medical University — Saint Petersburg, Russia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.